Medof M E, Kinoshita T, Nussenzweig V
J Exp Med. 1984 Nov 1;160(5):1558-78. doi: 10.1084/jem.160.5.1558.
Decay-accelerating factor (DAF), extracted from the stroma of human erythrocytes, was purified to homogeneity and incorporated into the membrane of sheep red cell complement intermediates, where its functional properties were analyzed. Incorporation of DAF into the cell membranes was temperature dependent, took place on pronase- or trypsin-treated erythrocytes, and did not depend on prior deposition of antibody, C1 or C4. Serum lipoproteins (high and low density) effectively inhibited DAF incorporation, but had no effect on the activity of DAF after its association with the cell membrane. The incorporated DAF could not be removed from the red cell surface by repeated washings in the presence of high salt concentration but was solubilized when the stroma were extracted with 0.1% Nonidet P-40. The presence of DAF in the membrane of EA did not affect the deposition of C1 and C4, but as few as 10(2) DAF molecules per cell profoundly inhibited the assembly of C3 and C5 convertases of both the classical and alternative pathways. The DAF inhibitory effect on EAC14 or EAC43 was not overcome by supplying an excess of C2 or factor B, but the alternative pathway C3 convertase could be assembled in the presence of Ni++, or nonphysiological concentrations of Mg++, which enhances the binding affinity of factor B for C3b. The DAF effect on EAC14 or EAC143 was entirely reversed by treating the cells with specific anti-DAF antibodies, showing that DAF did not alter the structure of C4b or C3b. Taken together, the experimental evidence suggests that DAF interacts directly with membrane-bound C3b or C4b and prevents subsequent uptake of C2 and factor B. DAF can function only within the cell membrane. Indeed, the decay dissociation of the C4b2a enzyme on DAF-containing sheep intermediates was not changed by varying the cell concentration. DAF-treated EA had no influence on the decay of nontreated EAC142 present in the same mixture. Moreover, the inhibitory activity of intact human erythrocytes on C4b2a was not blocked by antibodies to DAF, but was abolished by antibodies to the C3b/C4b receptor (CR1). When incorporated into the membrane of rabbit erythrocytes, human DAF inhibited their lysis by human complement. In conclusion, on the basis of these and previous results, it appears that DAF plays a central role in preventing the amplification of the complement cascade on host cell surfaces.(ABSTRACT TRUNCATED AT 400 WORDS)
衰变加速因子(DAF)从人红细胞基质中提取,经纯化至同质后整合到绵羊红细胞补体中间体的膜中,并在其中分析其功能特性。DAF整合到细胞膜中与温度有关,发生在经链霉蛋白酶或胰蛋白酶处理的红细胞上,且不依赖于抗体、C1或C4的预先沉积。血清脂蛋白(高密度和低密度)能有效抑制DAF的整合,但对DAF与细胞膜结合后的活性无影响。在高盐浓度下反复洗涤不能从红细胞表面去除整合的DAF,但用0.1%的诺乃洗涤剂P-40提取基质时可使其溶解。EA膜中DAF的存在不影响C1和C4的沉积,但每个细胞低至10²个DAF分子就能显著抑制经典途径和替代途径的C3和C5转化酶的组装。供应过量的C2或B因子不能克服DAF对EAC14或EAC43的抑制作用,但在Ni⁺⁺或非生理浓度的Mg⁺⁺存在下可组装替代途径C3转化酶,这会增强B因子与C3b的结合亲和力。用特异性抗DAF抗体处理细胞可完全逆转DAF对EAC14或EAC143的作用,表明DAF不会改变C4b或C3b的结构。综合来看,实验证据表明DAF直接与膜结合的C3b或C4b相互作用,并阻止随后C2和B因子的结合。DAF仅能在细胞膜内发挥作用。实际上,含DAF的绵羊中间体上C4b2a酶的衰变解离不受细胞浓度变化的影响。经DAF处理的EA对同一混合物中未处理的EAC142的衰变无影响。此外,完整人红细胞对C4b2a的抑制活性不受抗DAF抗体的阻断,但可被抗C3b/C4b受体(CR1)抗体消除。当整合到兔红细胞膜中时,人DAF可抑制其被人补体溶解。总之,基于这些及先前的结果,似乎DAF在防止补体级联反应在宿主细胞表面放大中起核心作用。(摘要截选至400字)